View Older Stories View More Recent Stories

Mar 2, 2022 02:15PM Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Feb 22, 2022 07:05AM Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Feb 22, 2022 07:05AM Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Feb 22, 2022 07:00AM Athira Pharma Inc. (ATHA) Reports Publication of Phase 1 Results for Fosgonimeton (ATH-1017)
Feb 22, 2022 07:00AM Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
Feb 22, 2022 07:00AM Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
Jan 31, 2022 07:06AM Athira Pharma Inc. (ATHA) Appoints Grant Pickering to its Board
Jan 31, 2022 07:00AM Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
Jan 31, 2022 07:00AM Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
Jan 25, 2022 07:00AM Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Jan 25, 2022 07:00AM Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Jan 5, 2022 07:03AM Athira Pharma Inc. (ATHA) Issues 2022 Outlook
Jan 5, 2022 07:00AM Athira Pharma Provides 2022 Pipeline Outlook
Jan 5, 2022 07:00AM Athira Pharma Provides 2022 Pipeline Outlook
Nov 10, 2021 04:05PM Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
Nov 10, 2021 04:05PM Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
Nov 10, 2021 11:50AM Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
Nov 10, 2021 11:50AM Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
Nov 8, 2021 07:00AM Athira Pharma to Present at Upcoming Investor Conferences
Nov 8, 2021 07:00AM Athira Pharma to Present at Upcoming Investor Conferences
Oct 29, 2021 07:00AM Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
Oct 29, 2021 07:00AM Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
Oct 22, 2021 08:22AM Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Oct 22, 2021 08:22AM Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Oct 21, 2021 04:14PM Athira Pharma Inc. (ATHA) Appoints Mark Litton as CEO and President; Rachel Lenington as COO
Oct 21, 2021 04:05PM Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
Oct 21, 2021 04:05PM Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
Sep 29, 2021 08:05AM Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Sep 29, 2021 08:05AM Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Aug 23, 2021 07:30AM Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
Aug 23, 2021 07:30AM Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
Aug 16, 2021 04:01PM Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
Aug 16, 2021 04:01PM Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
Aug 5, 2021 04:56PM Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
Aug 5, 2021 04:56PM Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
Jul 19, 2021 07:00AM Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
Jul 19, 2021 07:00AM Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
Jul 6, 2021 07:00AM Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
Jul 6, 2021 07:00AM Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
Jun 18, 2021 06:59AM Athira Pharma (ATHA) CEO Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University
Jun 17, 2021 05:00PM Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
Jun 17, 2021 05:00PM Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
Jun 14, 2021 07:00AM Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy
Jun 14, 2021 07:00AM Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy
Jun 9, 2021 07:00AM Athira Pharma to Present at Upcoming Investor Conferences
Jun 9, 2021 07:00AM Athira Pharma to Present at Upcoming Investor Conferences
Jun 1, 2021 07:00AM Athira Pharma Appoints Mark Worthington as General Counsel
Jun 1, 2021 07:00AM Athira Pharma Appoints Mark Worthington as General Counsel
May 26, 2021 07:00AM Athira Pharma to Present at Upcoming Investor Conferences
May 26, 2021 07:00AM Athira Pharma to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories